Revolution Medicines (RVMD) Current Deferred Revenue (2019 - 2023)

Revolution Medicines has reported Current Deferred Revenue for 5 years, with the latest figure at $1.4 million in Q1 2023.

• On a quarterly basis, Current Deferred Revenue fell 87.46% year-over-year to $1.4 million in Q1 2023; TTM through Mar 2023 was $1.4 million, a 87.46% decrease from a year earlier, with the FY2022 full-year figure at $4.5 million, down 63.92% from the prior year.
• Current Deferred Revenue was $1.4 million for Q1 2023 at Revolution Medicines, down from $4.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $17.1 million in Q4 2019, with the low at $1.4 million in Q1 2023.
• Average Current Deferred Revenue over 5 years is $11.0 million, with a median of $11.8 million recorded in 2020.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue grew 16.18% in 2022, then slumped 87.46% in 2023.
• Over 5 years, Current Deferred Revenue stood at $17.1 million in 2019, then fell by 29.27% to $12.1 million in 2020, then increased by 2.04% to $12.4 million in 2021, then slumped by 63.92% to $4.5 million in 2022, then plunged by 67.84% to $1.4 million in 2023.
• The last three Current Deferred Revenue figures came in at $1.4 million (Q1 2023), $4.5 million (Q4 2022), and $9.7 million (Q3 2022), per Business Quant data.